Teva agrees to settle US antitrust claims over QVAR for $35m
MLex Summary: Teva Pharmaceuticals agreed to pay $35 million to settle end-payor plaintiffs’ US claims accusing it of illegally delaying generic competition for QVAR, a line of brand name asthma inhalers....To view the full article, register now.
Already a subscriber? Click here to view full article